References
1. Stanley MM, Astwood EB. 1-methyl-2-mercaptoimidazole: An antithyroid compound highly active in man. Endocrinology 1949; 44: 588–589.
2. Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 1981; 6: 401–428.
3. Cooper DS. Treatment of thyrotoxicosis, in Braveman LE, Utiger RD (eds): Werner and Ingbars The Thyroid. Philadelphia, Lippincott-Raven, 1996, ed 7, pp 713–734.
4. Specht NW, Boehme EJ. Death due to agranulocytosis induced by methimazole therapy. JAMA 1952; 149: 1010–1011.
5. Rosenbaum H, Reveno WS. Agranulocytosis and toxic hepatitis from methimazole. JAMA 1953; 152: 27.
6. Shipp J. Jaundice during methimazole (Tapazole) administration. Ann Intern Med 1955; 42: 701–706.
7. Tennenbaum JI, Dreskin H. Toxic hepatitis during treatment with methimazole (Tapazole): Report of a case with apparent recovery. Ohio State Med J 1962; 58: 306–307.
8. Martinez-Lopez JI, Greenberg SE, Kling R. Drug-induced hepatic injury during methimazole therapy. Gastroenterology 1962; 43: 84–87.
9. Becker CF, Gorden P, Robbins J. Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. JAMA 1968; 206: 1787–1789.
10. Fisher MG, Nayer HR, Miller A. Methimazole-induced jaundice. JAMA 1973; 223: 1028–
PubMed |
CrossRef
11. Jansen PL, Froeling PG, Schade RW, et al. Intrahepatic cholestasis in hyperthyroidism and the effect of antithyroid and β-blocking drugs. Neth J Med 1982; 25: 318–324.
12. Schmidt G, Borsch G, Muller KM, et al. Methimazole-associated liver injury: Case report and brief literature review. Hepatogastroenterology 1986; 33: 244–246.
13. Arab D, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80: 1083–1085.
14. Schwab GP, Wetscher GJ, Vogl W, et al. Methimazole-induced liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir 1996; 381: 225–227.
15. Prost G, Dechavanne M, Levenq P, et al. Cholestatic jaundice caused by carbimazole [in French]. Nouv Presse Med 1973; 2: 2479(letter).
16. Dinsmore WW, O’Hara MD, Callender ME. Postanesthetic carbimazole jaundice. N Engl J Med 1983; 309: 438(letter).
17. Blom H, Stolk J, Schreuder HB, et al. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch Intern Med 1985; 145: 1513–1515.
18. Ayensa C, Diaz De Otazo R, Cia JM. Carbimazole-induced cholestatic hepatitis. Arch Intern Med 1986; 146: 1455(letter).
19. Epeirier JM, Pageaux GP, Coste V, et al. Fulminant hepatitis after carbimazole and propranolol administration. Eur J Gastroenterol Hepatol 1996; 8: 287–288.
20. Cales P, Voigt JJ, Suduca JM, et al. Cholestatic jaundice caused by carbimazole [in French]. Presse Med 1987; 16: 1005.
21. Ozenne G, Manchon ND, Doucet J, et al. Carbimazole-induced cholestatic jaundice. J Clin Gastroenterol 1989; 11: 95–97.
22. Sadoul JL, Canivet B, Freychet P. Toxic hepatitis induced by antithyroid drugs: Four cases including one with cross-reactivity between carbimazole and benzylthiouracil. Eur J Med 1993; 2: 473–477.
23. Kang H, Choi JD, Jung IG, et al. A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. Korean J Intern Med 1990; 5: 69–73.
24. Baker B, Shapiro B, Fig LM, et al. Unusual complications of antithyroid drug therapy: Four case reports and review of literature. Thyroidology 1989; 1: 17–26.
25. Lunzer M, Huang S, Ginsburg J, et al. Jaundice due to carbimazole. Gut 1975; 16: 913–917.
26. Yao JD, Gross JB Jr, Ludwig J, et al. Cholestatic jaundice in hyperthyroidism. Am J Med 1989; 86: 619–620.
27. Lersch C, Seige M, Natrath W, et al. Cholestasis induced by hyperthyroidism after liver transplantation. Digestion 1995; 56: 429–432.
28. Babini G, Gurioli L, Rizzi R, et al. Appearance of severe jaundice after radiometabolic treatment of thyrotoxicosis. J Endocrinol Invest 1999; 22: 209–211.
29. Anton Aranda A. Intrahepatic cholestasis in untreated hyperthyroidism [in Spanish]. Rev Esp Enferm Dig 2000; 92: 49–50.
30. Scanlon MF, Toft AD. Regulation of thyrotropin secretion, in Braveman LE, Utiger RD (eds): Werner and Ingbars The Thyroid. Philadelphia, Lippincott-Raven, 1996, ed 7, pp 220–240.
31. Ozenirler S, Tuncer C, Boztepe U, et al. Propylthiouracil-induced hepatic damage. Ann Pharmacother 1996; 30: 960–963.
32. Eisen MJ. Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 1953; 249: 814–816.
33. Maggiore G, Larizza D, Lorini R, et al. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr 1989; 8: 547–548.
34. Cooper DS, Bodes HH, Nath B, et al. Methimazole pharmacology in man: Studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984; 58: 473–479.
35. Methimazole, in Murray L (ed): Product Drug Reference. Montvale, NJ, Medical Economics Co., 2002, ed 56, pp 1823–1824.
36. Huang M, Li K, Wei JS, et al. Sequential liver and bone biochemical changes in hyperthyroidism: Prospective controlled follow-up study. Am J Gastroenterol 1994; 89: 1071–1076.